ERBB2 and gastric neoplasm: HER2 is overexpressed or amplified in 20% of gastric tumors and is predictive of trastuzumab efficacy [6], suggesting that this may provide a route to tumor cell survival that circumvents MET inhibition in a significant proportion of patients with GC.